Cite
HARVARD Citation
Willmann, S. et al. (2022). Model‐informed bridging of rivaroxaban doses for thromboprophylaxis in pediatric patients aged 9 years and older with congenital heart disease. CPT: pharmacometrics & systems pharmacology. pp. 1111-1121. [Online].